Other languages Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Real-time Estimate Cboe BZX Other stock markets 11:42:24 08/05/2024 pm IST			5-day change	1st Jan Change
80.58 ^USD	+10.06%		+13.50%	+13.50%

07/05	Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024
07/05	Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	08/05
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	07/05
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	03/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	03/04
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	27/02
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	27/02
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Ligand Pharmaceuticals Incorporated Announces Management Appointments	16/02
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication; Shares Jump Premarket	08/01
Ligand Pharma's at-home skin treatment gets FDA approval	06/01
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication	06/01
Ligand Pharma's topical skin drug gets US FDA approval	06/01
U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum	06/01
Ligand Pharmaceuticals Sets 2024 Earnings, Revenue Guidance	13/12
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024	12/12
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023	09/11
Ligand Pharmaceuticals Acquires Royalty on Sanofi's Diabetes Therapy for $20 Million in Cash	01/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Other languages

Filters